Register for a 1:1 here: https://go.oncehub.com/MichaelWells
Michael Wells is a Managing Director and Founder of Princeton Biopharma Capital Partners. Michael has had a long and distinguished career as an entrepreneur, healthcare investor, board member and chief executive.
Princeton Biopharma Capital was created for the purpose of providing growth capital to emerging health care companies. Michael is currently the acting Chairman and CEO of both Kaleo and Fidelis Animal Health both portfolio companies of Princeton Biopharma Capital. Prior to creating this investment company, he was the founder and CEO of Aton Pharma, a pharmaceutical company focused on rare diseases. For his part in creating and growing this company, he was named an Ernst & Young Entrepreneur of the Year in 2009. After selling Aton Pharma, he partnered with Cerberus Capital Management and invested in Covis Pharma where he was a board member for five years. His career began at Merck & Co. where he held a range of sales and marketing positions over eight years.
Michael holds a Bachelor of Science and a Master of Science from the University of Pittsburgh in addition to an MBA from The Wharton School. His current board appointments include Kaleo, Fidelis Animal Health, UPMC Hospital System and he is on the Board of Trustees at the University of Pittsburgh.
Michael Wells is a Managing Director and Founder of Princeton Biopharma Capital Partners. Michael has had a long and distinguished career as an entrepreneur, healthcare investor, board member and chief executive.
Princeton Biopharma Capital was created for the purpose of providing growth capital to emerging health care companies. Michael is currently the acting Chairman and CEO of both Kaleo and Fidelis Animal Health both portfolio companies of Princeton Biopharma Capital. Prior to creating this investment company, he was the founder and CEO of Aton Pharma, a pharmaceutical company focused on rare diseases. For his part in creating and growing this company, he was named an Ernst & Young Entrepreneur of the Year in 2009. After selling Aton Pharma, he partnered with Cerberus Capital Management and invested in Covis Pharma where he was a board member for five years. His career began at Merck & Co. where he held a range of sales and marketing positions over eight years.
Michael holds a Bachelor of Science and a Master of Science from the University of Pittsburgh in addition to an MBA from The Wharton School. His current board appointments include Kaleo, Fidelis Animal Health, UPMC Hospital System and he is on the Board of Trustees at the University of Pittsburgh.